Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
Rheumatic Heart Disease III: Medical Management01:21

Rheumatic Heart Disease III: Medical Management

544
Rheumatic heart disease (RHD) management can be divided into two main strategies: prevention and long-term management.Primary PreventionPrimary prevention focuses on timely diagnosis and management of group A streptococcal pharyngitis to prevent acute rheumatic fever. The most widely used antibiotic for treating this condition is intramuscular benzathine penicillin G.Acute Rheumatic Fever TreatmentThe primary treatment goal for a patient diagnosed with acute rheumatic fever is to suppress the...
544
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
1.1K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.9K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.9K
Rheumatic Heart Disease IV: Nursing Management01:20

Rheumatic Heart Disease IV: Nursing Management

484
AssessmentA comprehensive assessment is essential in managing a patient with rheumatic heart disease (RHD). Begin with obtaining a detailed medical history, including recent streptococcal infections, a history of rheumatic fever, or previously diagnosed rheumatic heart disease. Assess the patient for symptoms such as fever, chest pain, widespread joint pain (arthralgia), tachycardia, pericardial friction rub, muffled heart sounds, heart murmurs, peripheral edema, subcutaneous nodules, and...
484

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Lung cancer in Argentina: a modelling study of disease and economic burden.

Public health·2024
Same author

Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland.

RMD open·2020
Same author

Long-term immunogenicity after yellow fever vaccination in immunosuppressed and healthy individuals.

Vaccine·2020
Same author

Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.

Scandinavian journal of rheumatology·2018
Same author

Distinct expression of interleukin (IL)-36α, β and γ, their antagonist IL-36Ra and IL-38 in psoriasis, rheumatoid arthritis and Crohn's disease.

Clinical and experimental immunology·2015
Same author

[Soft tissue rheumatic disorders: important for general practice].

Revue medicale suisse·2015
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

Revue medicale suisse·2026
Same journal

[Erythema multiforme : target deciphering].

Revue medicale suisse·2026
See all related articles

Related Experiment Video

Updated: May 1, 2026

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

1.5K

[Disease modifying antirheumatic drugs].

K Luong Ba, C Gabay

    Revue Medicale Suisse
    |April 8, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Effective rheumatoid arthritis treatment, including early diagnosis and specialist follow-up, significantly improves patient outcomes. Various disease-modifying drugs, from conventional to biologic and targeted therapies, are available, with new options emerging.

    More Related Videos

    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
    07:37

    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

    Published on: June 6, 2025

    1.5K

    Related Experiment Videos

    Last Updated: May 1, 2026

    Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
    04:50

    Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

    Published on: May 16, 2025

    1.5K
    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
    07:37

    An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

    Published on: June 6, 2025

    1.5K

    Area of Science:

    • Rheumatology
    • Immunology
    • Pharmacology

    Context:

    • Rheumatoid arthritis (RA) historically led to high morbidity.
    • Modern treatments have significantly altered the disease's natural history.
    • Achieving remission or low disease activity is key for functional outcomes.

    Purpose:

    • To review the current landscape of rheumatoid arthritis treatment.
    • To highlight the importance of early diagnosis and specialist management.
    • To discuss available and emerging therapeutic options for RA.

    Summary:

    • Appropriate treatment, including early diagnosis and specialist care, is crucial for managing rheumatoid arthritis (RA) and improving patient function.
    • Disease-modifying anti-rheumatic drugs (DMARDs) encompass conventional (e.g., methotrexate), biologic (e.g., TNF-inhibitors, abatacept, tocilizumab, rituximab), and targeted synthetic (e.g., tofacitinib) therapies.
    • Ongoing research promises novel treatments to enhance RA management further.

    Impact:

    • Improved functional outcomes for patients with rheumatoid arthritis.
    • Enhanced ability for rheumatologists to manage RA effectively.
    • Potential for better disease control and quality of life in RA patients.